Tag: Ono Pharmaceutical

Bayer, BMS and Ono in Clinical Collaboration Agreement

pills
Bayer, Bristol-Myers Squibb Company and Ono Pharmaceutical Co.,Ltd. (“Ono”) announced today that the three companies have entered into a clinical collaboration agreement to evaluate the combination of...

Forty Seven and Ono Agreed to Develop Monoclonal Antibody Against CD47

agreement
Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, and Ono Pharmaceutical Co., Ltd. announced an exclusiv...

Ono and Rafael Signed Exclusive License Agreement

Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, announced that it has entered into an out-licensing agreement with Ono Pharmaceutical Co., Ltd., a ...

Nobel Laureate is Demanding More Money from Ono Pharma for Cancer Drug

Nobel laureate Tasuku Honjo said Wednesday he is involved in a dispute over license fees under a patent agreement with Ono Pharmaceutical Co., which sells a cancer treatment drug developed based on hi...

Ono Pharmaceutical and twoXAR in R&D Collaboration

Ono Pharmaceutical Co., Ltd., a Japanese pharmaceutical research and development company, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, announced today that the c...

Repare Therapeutics’ Polθ Inhibitor Heads for Asia

Repare Therapeutics, Inc., a privately held precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in clearly defined pa...